Guggenheim Initiates Coverage On Castle Biosciences With Buy Rating, Announces Price Target of $25
Guggenheim Initiates Coverage On Castle Biosciences With Buy Rating, Announces Price Target of $25
古根海姆以買入評級啓動對城堡生物科學的報道,宣佈目標股價爲25美元
Guggenheim analyst Subbu Nambi initiates coverage on Castle Biosciences (NASDAQ:CSTL) with a Buy rating and announces Price Target of $25.
古根海姆分析師Subbu Nambi以買入評級開始對Castle Biosciences(納斯達克股票代碼:CSTL)進行報道,並宣佈目標股價爲25美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。